Zogenix (ZGNX) Prices 8.52M Share Common Offering at $23/Sh

After-Hours Stock Movers 03/03: (CVET) (INO) (AMBA) Higher; (CLDX) (HIIQ) (JWN) Lower (more...)

March 3, 2020 5:24 PM EST

Today's After-Hours Stock Movers

Cardlytics (NASDAQ: CDLX) 27.8% LOWER; reported Q4 EPS of $0.18, $0.14 better than the analyst estimate of $0.04. Revenue for the quarter came in at $69.3 million versus the consensus estimate of $63.89 million. Cardlytics sees Q1 2020 revenue of $43.5-46.5 million vs $52.77 million expected.

Covetrus (NASDAQ: CVET) 14.4% HIGHER; reported Q4 EPS of ($0.33), $0.45 worse than the analyst estimate of $0.12. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $986.26 million. Covetrus sees FY2020 revenue of $4.025-4.125 billion, versus the consensus of... More

Zogenix (ZGNX) Plans Public Offering of Common Stock

March 3, 2020 5:08 PM EST

Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the... More

Zogenix, Inc. (ZGNX) PT Lowered to $45 at SVB Leerink

March 3, 2020 9:13 AM EST

SVB Leerink analyst Marc Goodman lowered the price target on Zogenix, Inc. (NASDAQ: ZGNX) to $45.00 (from $48.00) while maintaining a Outperform rating.... More

Zogenix, Inc. (ZGNX) PT Lowered to $60 at Stifel

March 3, 2020 4:31 AM EST

Stifel analyst Paul Matteis lowered the price target on Zogenix, Inc. (NASDAQ: ZGNX) to $60.00 (from $67.00) while maintaining a Buy rating.... More

Zogenix (ZGNX) Misses Q4 EPS by 20c, Revenues Beat

March 2, 2020 4:02 PM EST

Zogenix (NASDAQ: ZGNX) reported Q4 EPS of ($1.26), $0.20 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $1.95 thousand versus the consensus estimate of $440 thousand.

Fourth Quarter 2019 Financial Results

The Company recorded $1.9 million in revenue for the fourth quarter ended December 31, 2019, as a result of its March 2019 collaboration with Nippon Shinyaku Co., Ltd. for FINTEPLA in Dravet syndrome and LGS in Japan. Zogenix recorded no revenue for the corresponding period of 2018.Research and development expenses for the fourth quarter ended December 31, 2019, totaled $35.8 million, up from $23.6 million in the fourth quarter... More